Azitra brings in $14m Series A to advance microbiome skin therapies
Connecticut-based microbiome therapy company Azitra recently announced a $14 million haul in Series A funding. The round was led by KdT Ventures and previous investor Bios Partners, along with Godfrey Capital and Connecticut Innovations. Azitra, which focuses on dermatologic conditions, will
SurgiMab – Phase 3 Trial Evaluating a Novel Fluorescent Tumor-specific Antibody for the Improvement of Surgical Outcomes in Colorectal Cancer Patients
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, announces that the first US patient has been recruited into its on-going pivotal Phase 3 clinical trial
Chugai Renews License to EpiVax’s ISPRI In Silico Toolkit for Immunogenicity Assessment
Chugai, one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products, integrated the advanced ISPRI toolkit into their preclinical assessment pipeline after an extended head-to-head comparison with other in silico tools in September 2013. This 3-year extension will
Pepticom Raises $5 Million in Series A Funding
Pepticom's unique artificial intelligence (AI) technology streamlines and significantly accelerates the ability of researchers to discover advanced peptide-based drug candidates. Peptides are used in various therapies, and are recognized for being highly selective and efficacious as well as relatively safe.
Abalos Therapeutics Launches with €12M Series A
Abalos Therapeutics launches with €12M in Series A funding to get the development of its arenavirus-based cancer therapies off the ground. Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the investment round, with additional contributions from NRW.BANK and High-Tech Gründerfonds. Abalos, which
Cell transdifferentiation specialist Mogrify Ltd raises US$16m
British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund
ADC Therapeutics enters licence option deal with Avacta Group
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates. Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind
Healx Ltd raises $56m in Series B financing
AI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases. The financing was led by Atomico and joined by Intel Capital, Global Brain and btov Partners as new
Creoptix AG closes CHF8m financing round
Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion. The financing round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation as well as existing private investors. Upon
Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk
The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz